Navigation Links
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium

DALLAS Nov. 23, 2009 UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

The ICAC, which receives funding through the NIH's National Institute of Allergy and Infectious Diseases, investigates novel treatments and causes of asthma in urban children.

Dr. Rebecca Gruchalla, chief of allergy and immunology at UT Southwestern, said continued funding of the consortium is imperative because morbidity and mortality continues to be highest in inner-city children and adolescents with asthma. Dr. Gruchalla has led the Dallas arm of the ICAC for seven years.

"The proposed studies undertaken through our continued role in the ICAC are novel, innovative and likely to help us truly make a difference in the lives of inner-city children suffering from this often debilitating disease," Dr. Gruchalla said.

Ongoing studies include a prospective, longitudinal evaluation of environmental factors that influence the development of the immune system and asthma, as well as clinical trials of possible treatment therapies.

Previous ICAC-funded research has found that:

  • A coordinated, guidelines-based approach to asthma management quickly controls asthma among inner-city adolescents.
  • Adding exhaled nitric oxide to guidelines-based care does not improve clinical outcomes.
  • Screening tests used to predict asthma activity in some patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens.

With continued NIH funding, Dr. Michelle Gill, assistant professor of pediatrics at UT Southwestern, is leading key mechanistic studies that explore how anti-IgE therapy can decrease viral-induced seasonal asthma exacerbations. IgE antibodies are the fuel in the immune system that perpetuates asthmatic reactions and can make asthma worse in people who are sensitive to particular allergens.

"The goal of our mechanistic studies is to define how allergens interfere with immune responses to respiratory viruses. We will also investigate whether anti-IgE therapy improves these responses to seasonal viral infections in patients with asthma," Dr. Gill said.

The consortium is administered by the University of Wisconsin-Madison. In addition to UT Southwestern, research is being conducted at Boston University School of Medicine; Children's Memorial Hospital in Chicago; George Washington University School of Medicine and Health Sciences in Washington, D.C.; National Jewish Health in Denver; Johns Hopkins University School of Medicine; University of California, San Francisco; Columbia University College of Physicians and Surgeons in New York City; and the Henry Ford Hospital in Detroit.


Contact: Erin Prather Stafford
UT Southwestern Medical Center

Related medicine news :

1. Director of UT Southwestern center honored with first international neurology medal
2. UT Southwestern Responds to VA Announcement
3. UT Southwestern physicians bust myths about insulin
4. UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer
5. Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find
6. Higher drug doses needed to defeat tuberculosis, UT Southwestern researchers report
7. UT Southwestern, UT Arlington to develop magnetic surgery tools
8. UT Southwestern researcher named HHMI Early Career Physician-Scientist
9. Former Gov. Bill Clements Makes Historic Gift to UT Southwestern With $100 Million Transformative Contribution
10. UT Southwesterns Olson wins prestigious French award for heart research
11. Participants in antidepressant drug trials are atypical patients, UT Southwestern researchers report
Post Your Comments:
Related Image:
UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: